1269025-90-2

Upstream product

• 150-19-6 O-methylresorcine 
• 1269025-89-9 ethyl 6-ethyl-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(2,2,2-trifluoroethoxy)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate 
• 1269024-73-8 ethyl 5-bromo-6-ethyl-1-methyl-3-(2,2,2-trifluoroethoxy)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate 
• 1269024-72-7 ethyl 5-bromo-6-ethyl-3-hydroxy-1-methyl-1H-pyrrolo[2,3-b]pyridine-2-carboxylate 
• 1269024-71-6 ethyl 5-bromo-2-chloro-6-ethylpyridine-3-carboxylate 
• 1269024-70-5 ethyl 5-bromo-6-ethyl-2-oxo-1,2-dihydropyridine-3-carboxylate 
• 1269024-68-1 ethyl 6-ethyl-2-oxo-1,2-dihydropyridine-3-carboxylate 
• 1186188-51-1 ethyl 4-chloro-6-ethyl-2-oxo-1,2-dihydropyridine-3-carboxylate 
• 125604-20-8 ethyl 6-ethyl-4-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxylate 
• 883528-73-2 3-amino-4-methyl crotonic acid methylester 
• 30414-53-0 methyl propanoyl acetate 

Relevant academic research and scientific papers

FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF

The present invention provides a fused heterocycle derivative having a strong Smo inhibitory activity, and use thereof. Specially, the present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or salt thereof, and a medicament containing the compound or a prodrug thereof, which is an Smo inhibitor or an agent for the prophylaxis or treatment of cancer.